AR and posterior cortical atrophy: In preclinical studies, NEO2734 has been shown to be efficacious against SPOP-mutant PCa which carries abundant BET proteins due to impaired degradation [83] and suppress the expression of non-canonical oncogenic AR target genes in enzalutamide-resistant cell lines [84].